Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver Sells 8,996 Shares

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 8,996 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total value of $119,286.96. Following the transaction, the chief financial officer now directly owns 173,583 shares in the company, valued at approximately $2,301,710.58. The trade was a 4.93 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Sandra Beaver also recently made the following trade(s):

• On Monday, December 23rd, Sandra Beaver sold 1,586 shares of Evolus stock. The stock was sold at an average price of $10.85, for a total value of $17,208.10.

Evolus Stock Performance

Shares of EOLS traded down $0.22 during mid-day trading on Thursday, hitting $13.25. 663,321 shares of the company’s stock were exchanged, compared to its average volume of 593,757. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The firm has a market capitalization of $842.53 million, a P/E ratio of -14.56 and a beta of 1.28. Evolus, Inc. has a fifty-two week low of $9.25 and a fifty-two week high of $17.82. The business’s 50 day moving average is $13.30 and its two-hundred day moving average is $13.92.

Analysts Set New Price Targets

Several equities analysts have issued reports on the company. Barclays raised their price objective on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Evolus in a report on Wednesday, March 5th. Finally, HC Wainwright reiterated a “buy” rating and set a $27.00 target price on shares of Evolus in a research note on Wednesday, March 5th.

Institutional Investors Weigh In On Evolus

A number of hedge funds have recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. acquired a new stake in Evolus in the fourth quarter valued at about $753,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Evolus by 6.3% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 115,052 shares of the company’s stock valued at $1,270,000 after purchasing an additional 6,821 shares during the period. Zimmer Partners LP lifted its position in Evolus by 66.6% in the fourth quarter. Zimmer Partners LP now owns 416,500 shares of the company’s stock valued at $4,598,000 after purchasing an additional 166,500 shares during the period. Tang Capital Management LLC lifted its position in Evolus by 3.1% in the fourth quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock valued at $55,171,000 after purchasing an additional 150,000 shares during the period. Finally, Rafferty Asset Management LLC acquired a new stake in Evolus in the fourth quarter valued at about $115,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.